Lung Cancer Trials Ask AI to find trials
CompletedPhase 1NCT03898791
Official study title

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

Study summary

The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedLY3295668 Erbumine

The study team can explain what participation involves.

Who it may be forSmall cell lung cancer (SCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 5, 2021 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?40 U.S. locations

Locations may change over time.

Who runs it?Eli Lilly and Company

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Eli Lilly and Company
Interventions being studied
Drug: LY3295668 Erbumine
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Small cell lung cancer (SCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Have histological or cytological evidence of a diagnosis of platinum sensitive small cell lung cancer that is extensive stage.
  • Have adequate organ function.
  • Have a performance status (PS) of ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale.
  • Have discontinued previous treatments for cancer.
  • Are able to swallow capsules.
Reasons someone may not be able to joinExclusion criteria
  • Currently enrolled in a clinical study.
  • Have a serious concomitant systemic disorder.
  • Have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C.
  • Have a significant cardiac condition.
  • Have previously received an aurora kinase inhibitor.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Highlands Oncology GroupFayetteville, Arkansas
  • Rocky Mountain Cancer CenterDenver, Colorado
  • H Lee Moffitt Cancer CenterTampa, Florida
  • Massachusetts General HospitalBoston, Massachusetts
  • Dana Farber Cancer InstituteBoston, Massachusetts
  • Washington University Medical SchoolSt Louis, Missouri
  • Dartmouth Hitchcock Medical CenterLebanon, New Hampshire
  • Memorial Sloan Kettering Cancer CenterNew York, New York
  • Levine Cancer Institute- Carolinas Medical CenterCharlotte, North Carolina
  • University of Pittsburgh Medical CenterPittsburgh, Pennsylvania
  • Prisma Health Cancer InstituteGreenville, South Carolina
  • Texas Oncology Cancer CenterAustin, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 5, 2021. Always confirm current availability with the study team.

View original record ↗